Published on 27/12/2025
Presenting Risks and Benefits Clearly to Clinical Trial Participants
Introduction: The Importance of Risk-Benefit Disclosure
Transparency in presenting risks and benefits is a critical component of informed consent in clinical trials. Participants must fully understand what they are agreeing to, and regulatory bodies such as the FDA, EMA, and ICH-GCP emphasize clarity, accuracy, and balance in disclosure. Misrepresentation or omission of risks can compromise trial integrity, lead to ethical violations, and even result in regulatory penalties. Conversely, overstating benefits may create undue expectations, which can influence decision-making and reduce trust.
This tutorial provides practical, step-by-step guidance for clinical trial professionals on how to present risks and benefits transparently in informed consent forms (ICFs) and during discussions with participants.
Regulatory Expectations: What Must Be Disclosed
ICH-GCP section 4.8 requires investigators to provide a comprehensive explanation of potential risks and benefits to participants. Regulators mandate that disclosure must be:
- ✅ Complete – All known and reasonably foreseeable risks must be explained
- ✅ Balanced – Benefits must not be exaggerated and should be stated realistically
- ✅ Understandable – Language must be accessible to participants, avoiding jargon
- ✅ Ongoing – Updates must be shared as new safety information emerges
For example,
Strategies for Communicating Risks
Risk communication should be tailored for participant comprehension. Key strategies include:
- ➤ Use plain language to describe medical terms (e.g., “liver damage” instead of “hepatotoxicity”)
- ➤ Quantify risks using frequencies (“1 in 100 participants may experience…”) rather than vague terms like “rare”
- ➤ Include both common and serious risks, clearly differentiating between them
- ➤ Avoid minimizing risks with reassuring language that could undermine objectivity
Visual aids such as bar graphs or pictograms can also be highly effective in helping participants grasp relative risk levels.
Strategies for Communicating Benefits
While benefits must be presented to ensure balance, they should not be overstated. ICH-GCP requires that benefits be framed realistically:
- ✅ Clarify whether benefits are direct (participant health improvement) or indirect (contribution to science)
- ✅ Avoid guaranteeing therapeutic benefit in early-phase studies
- ✅ Provide sample outcomes from past trials where relevant, but note uncertainties
For example, in an investigational vaccine trial, the benefit may be described as “potential protection against disease if the vaccine proves effective,” not as “this vaccine will protect you.”
Sample Risk-Benefit Table for Consent Forms
| Risk/Benefit | Description | How It Is Communicated |
|---|---|---|
| Common Side Effect | Mild headache in 20% of participants | “1 in 5 may have mild headache” |
| Serious Risk | Liver toxicity in 1% of participants | “1 in 100 may develop liver issues requiring monitoring” |
| Potential Benefit | May reduce symptoms of chronic disease | “This treatment may or may not improve your symptoms” |
| Indirect Benefit | Contribution to advancing medical science | “Your participation helps future patients” |
Case Study: Miscommunication in Risk Disclosure
In a cardiovascular trial in 2019, regulators identified that the consent form listed “possible side effects” but failed to specify the frequency of arrhythmia events, which had already been observed in Phase II studies. This omission led to an FDA Form 483 observation, requiring immediate re-consent of participants and training of site staff on risk communication.
This case highlights the regulatory expectation that both the nature and likelihood of risks must be disclosed in clear and quantifiable terms.
Checklist for Transparent Risk-Benefit Disclosure
- ✅ Are all foreseeable risks clearly listed?
- ✅ Are risks quantified rather than described vaguely?
- ✅ Are potential benefits described realistically?
- ✅ Is the language understandable to a lay audience?
- ✅ Is there a process for updating participants on new risks?
External Resources
Professionals can access guidance on transparent disclosure from regulatory agencies and trial registries. For instance, the NIHR’s Be Part of Research platform offers resources on how risks and benefits should be communicated in ongoing studies.
Conclusion: Building Trust Through Transparency
Clear, accurate, and balanced disclosure of risks and benefits is both a regulatory requirement and an ethical obligation. Transparent communication empowers participants to make informed choices, strengthens trial credibility, and ensures compliance with ICH-GCP and global regulations. By using structured communication strategies, visual tools, and ongoing updates, sponsors and investigators can uphold participant rights and foster long-term trust in clinical research.